摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

( 5-methyl-1,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone

中文名称
——
中文别名
——
英文名称
( 5-methyl-1,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone
英文别名
(5-Methyl-1,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone;(5-methyl-4,6,7,8-tetrahydro-1H-pyrazolo[4,3-c]azepin-3-yl)-[4-[2-(trifluoromethyl)phenyl]piperidin-1-yl]methanone
( 5-methyl-1,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone化学式
CAS
——
化学式
C21H25F3N4O
mdl
——
分子量
406.451
InChiKey
XXKCZIIAHTUBCA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    29
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    52.2
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160046648A1
    公开(公告)日:2016-02-18
    The present invention provides a compound having the structure: (structurally represented) wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl; R 6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.
    本发明提供了一种化合物,其结构为:(结构式表示),其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基;R6为H、OH或卤素;B为取代或未取代杂环、吡嗪、吡唑、吡嗪、噻二唑或三唑,其中杂环不是氯取代的吲哚;当吡唑取代时,取代基不是三氟甲基,或其药学上可接受的盐。
  • 4-phenylpiperidines, their preparation and use
    申请人:The Trustees of Columbia University in the City of New York
    公开号:US10273243B2
    公开(公告)日:2019-04-30
    The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:(结构表示),其中 R1、R2、R3、R4 和 R5 各自独立地为 H、卤素、CF3 或 C1-C4 烷基;R6 为 H、OH 或卤素;B 为取代或未取代的杂环、哒嗪、吡唑、吡嗪、噻二唑或三唑,其中杂环为氯取代的吲哚以外的杂环;吡唑取代时为三氟甲基以外的取代基,或其药学上可接受的盐。
  • Methods of treating metabolic diseases with fused bicyclic pyrazoles
    申请人:BELITE BIO, INC
    公开号:US11389444B2
    公开(公告)日:2022-07-19
    Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
    本文提供了可用于治疗视网膜结合蛋白(RBP4)相关疾病(如肥胖症等)的杂环衍生物化合物和包含上述化合物的药物组合物。
  • FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE
    申请人:Belite Bio, LLC
    公开号:EP3996714A1
    公开(公告)日:2022-05-18
  • METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES
    申请人:BELITE BIO, INC
    公开号:US20200197390A1
    公开(公告)日:2020-06-25
    Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
查看更多